Adenoviral vector incorporating zipper peptide-modified fiber protein and uses thereof
AssigneeVectorlogics, Inc.
InventorsNikolay Korokhov, Galina Mikheeva
Life of this patent
Estimating the term…
Abstract
The present invention provides a recombinant adenovirus vector targeted by zipper peptides. The vector contains a fiber protein modified by insertion of a first zipper peptide that can crosslink to a fusion protein comprising a second zipper peptide and a targeting ligand. Binding of the first zipper peptide to the second zipper peptide forms a targeted vector: ligand complex, thereby targeting the adenovirus vector to a cell that expresses a cell surface molecule that binds to said targeting ligand.
Claims16
A targeted recombinant adenovirus vector, comprising:
- (i) a gene encoding a heterologous protein;
- (ii) a modified fiber protein comprising a first zipper peptide, wherein said first zipper peptide is capable of forming heteroduplex with a second zipper peptide via formation of coiled coils;
- and
- (iii) a gene encoding a fusion protein comprising said second zipper peptide and a targeting ligand, wherein binding of said first zipper peptide to said second zipper peptide connects said targeting ligand to said modified fiber protein, thereby targeting said adenovirus vector to a cell that expresses a cell surface molecule that binds to said targeting ligand.
A CD40-targeted recombinant adenovirus vector, comprising:
- (i) a gene encoding a heterologous protein;
- (ii) a modified fiber protein comprising a first zipper peptide, wherein said first zipper peptide is capable of forming heteroduplex with a second zipper peptide via formation of coiled coils;
- and
- (iii) a gene encoding a fusion protein comprising said second zipper peptide and a targeting ligand selected from the group consisting of CD40 ligand and a single chain fragment (scFv) of anti-human CD40 antibody, wherein binding of said first zipper peptide to said second zipper peptide connects said targeting ligand to said modified fiber protein, thereby targeting said adenovirus vector to a CD40+ cell.
Dependencies are inferred from the claim text.